These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 33109311)

  • 1. Allergic inflammation of the anterior surface of the eye.
    Bielory L
    Allergy Asthma Proc; 2020 Nov; 41(6):449-453. PubMed ID: 33109311
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of ketotifen fumarate ophthalmic solution alone, desloratadine alone, and their combination for inhibition of the signs and symptoms of seasonal allergic rhinoconjunctivitis in the conjunctival allergen challenge model: a double-masked, placebo- and active-controlled trial.
    Crampton HJ
    Clin Ther; 2003 Jul; 25(7):1975-87. PubMed ID: 12946545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The added benefit of local Patanol therapy when combined with systemic Claritin for the inhibition of ocular itching in the conjunctival antigen challenge model.
    Abelson MB; Lanier RQ
    Acta Ophthalmol Scand Suppl; 1999; (228):53-6. PubMed ID: 10337434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The allergic eye: recommendations about pharmacotherapy and recent therapeutic agents.
    Kimchi N; Bielory L
    Curr Opin Allergy Clin Immunol; 2020 Aug; 20(4):414-420. PubMed ID: 32558665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Oral second generation antihistamines in allergic rhinitis].
    Riechelmann H
    Laryngorhinootologie; 2005 Jan; 84(1):30-41. PubMed ID: 15647976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating the efficacy of epinastine ophthalmic solution using a conjunctivitis allergen challenge model in patients with birch pollen allergic conjunctivitis.
    Tagawa Y; Namba K; Nakazono Y; Iwata D; Ishida S
    Allergol Int; 2017 Apr; 66(2):338-343. PubMed ID: 27720602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levocabastine. An update of its pharmacology, clinical efficacy and tolerability in the topical treatment of allergic rhinitis and conjunctivitis.
    Noble S; McTavish D
    Drugs; 1995 Dec; 50(6):1032-49. PubMed ID: 8612470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, double-masked comparison of olopatadine ophthalmic solution, mometasone furoate monohydrate nasal spray, and fexofenadine hydrochloride tablets using the conjunctival and nasal allergen challenge models.
    Spangler DL; Abelson MB; Ober A; Gotnes PJ
    Clin Ther; 2003 Aug; 25(8):2245-67. PubMed ID: 14512132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effects of emedastine eyedrops on acute seasonal allergic conjunctivitis in children].
    Endre L
    Orv Hetil; 2003 Apr; 144(14):665-7. PubMed ID: 12795028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allergic conjunctivitis and H1 antihistamines.
    del Cuvillo A; Sastre J; Montoro J; Jáuregui I; Dávila I; Ferrer M; Bartra J; Mullol J; Valero A
    J Investig Allergol Clin Immunol; 2009; 19 Suppl 1():11-8. PubMed ID: 19476049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children.
    Abelson MB; Torkildsen GL; Williams JI; Gow JA; Gomes PJ; McNamara TR;
    Clin Ther; 2009 Sep; 31(9):1908-21. PubMed ID: 19843481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medical therapy for ocular allergy.
    Trocme SD; Raizman MB; Bartley GB
    Mayo Clin Proc; 1992 Jun; 67(6):557-65. PubMed ID: 1359206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allergic Conjunctivitis Management: Update on Ophthalmic Solutions.
    Leonardi A; Quintieri L; Presa IJ; LLoves JM; Montero J; Benítez-Del-Castillo JM; Lestón FJS; González-Mancebo E; Asero R; Groblewska A; Kuna P
    Curr Allergy Asthma Rep; 2024 Jul; 24(7):347-360. PubMed ID: 38869807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral and topical antihistamines: pharmacologic properties and therapeutic potential in ocular allergic disease.
    Jaanus SD
    J Am Optom Assoc; 1998 Feb; 69(2):77-87. PubMed ID: 9549258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A current appreciation of sites for pharmacological intervention in allergic conjunctivitis: effects of new topical ocular drugs.
    Yanni JM; Sharif NA; Gamache DA; Miller ST; Weimer LK; Spellman JM
    Acta Ophthalmol Scand Suppl; 1999; (228):33-7. PubMed ID: 10337430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of epinastine hydrochloride ophthalmic solution in allergic conjunctivitis by conjunctival cedar pollen allergen challenge.
    Fujishima H; Ohashi Y; Takamura E
    Ann Allergy Asthma Immunol; 2014 Oct; 113(4):476-81. PubMed ID: 25163405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of bilastine upon the ocular symptoms of allergic rhinoconjunctivitis.
    Bartra J; Mullol J; Montoro J; Jáuregui I; del Cuvillos A; Dávila I; Ferrer M; Sastre J; Valero A
    J Investig Allergol Clin Immunol; 2011; 21 Suppl 3():24-33. PubMed ID: 22185047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An open-label, investigator-masked, crossover study of the ocular drying effects of two antihistamines, topical epinastine and systemic loratadine, in adult volunteers with seasonal allergic conjunctivitis.
    Ousler GW; Workman DA; Torkildsen GL
    Clin Ther; 2007 Apr; 29(4):611-6. PubMed ID: 17617284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fundamental Aspects and Relevance of Components in Antihistamine Eye Drops.
    Herrero-Vanrell R; Jáuregui Presa I; Leceta Bilbao A; Montero-Iruzubieta J
    J Investig Allergol Clin Immunol; 2023 Dec; 33(6):431-438. PubMed ID: 38095492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative evaluation of olopatadine ophthalmic solution (0.1%) versus ketorolac ophthalmic solution (0.5%) using the provocative antigen challenge model.
    Deschenes J; Discepola M; Abelson M
    Acta Ophthalmol Scand Suppl; 1999; (228):47-52. PubMed ID: 10337433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.